Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Round 1

WASHINGTON - Despite a flurry of publicity last week surrounding the U.S. Patent and Trademark Office's decision to revoke broad claims granted to Agracetus for all genetically modified forms of cotton, the patents will remain valid and enforceable during an appeals process that could last two years.

Patent office officials also moved to characterize the decision to rescind the claims as one based on the discovery of prior disclosure of the invention, rather

Read the full 727 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE